FDA Approves Inhaled COPD Drug

The FDA has approved Breo Ellipta, an inhaled drug, for use as treatment for chronic obstructive pulmonary disease, or COPD. It is designed to be a once-daily maintenance treatment and trials have indicated that it might cause fewer serious side effects than other COPD drugs.

Breo Ellipta reduces lung inflammation and helps relax airway muscles. It is approved to reduce COPD exacerbations in patients with a history of exacerbations.

The treatment is expected to be available by the third quarter of 2013.

To learn more, click here.